Skip to content

Matthias E. Liechti

University Hospital of Basel, University of Basel

176 papers in the library · 10,050 citations · publishing 2000-2026

Papers

Sort Most recent Most cited

Long-lasting subjective effects of LSD in normal subjects

Psychopharmacology September 16, 2017 Yasmin Schmid, Matthias E. Liechti 234 citations

RATIONALE: Lysergic acid diethylamide (LSD) and other serotonergic hallucinogens can induce profound alterations of consciousness and mystical-type experiences, with reportedly long-lasting effects on subjective well-being and personality. METHODS: We investigated the lasting effects of a single dose of LSD (200 μg) that was administered in a laboratory setting in 16 healthy participants. The...

First Time View on Human Metabolome Changes after a Single Intake of 3,4-Methylenedioxymethamphetamine in Healthy Placebo-Controlled Subjects

Journal of Proteome Research July 19, 2017 Martina I. Boxler, Matthias E. Liechti, Yasmin Schmid et al. 17 citations

3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is widely consumed recreationally. Little is known about its effects on the human metabolome. Mapping biochemical changes after drug exposure can complement traditional approaches by revealing potential biomarkers of organ toxicity or discovering new metabolomic features in a time- and dose-dependent manner. We aimed to analyze for the first...

DOI: 10.1021/acs.jproteome.7b00294 (opens in new tab) Metabolome Placebo Pharmacology Metabolite +1

A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects

Frontiers in Pharmacology June 28, 2017 Patrick C. Dolder, Edna Grünblatt, Felix Müller et al. 12 citations

Rationale Renewed interest has been seen in the use of lysergic acid diethylamide (LSD) in psychiatric research and practice. The repeated use of LSD leads to tolerance that is believed to result from serotonin (5-HT) 5-HT2A receptor downregulation. In rats, daily LSD administration for 4 days decreased frontal cortex 5-HT2A receptor binding. Additionally, a single dose of LSD acutely increased...

Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects

Psychopharmacology May 27, 2017 Patrick C. Dolder, Felix Müller, Yasmin Schmid et al. 118 citations

RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally and investigated as an adjunct to psychotherapy. Methylphenidate and modafinil are psychostimulants that are used to treat attention-deficit/hyperactivity disorder and narcolepsy, respectively, but they are also misused as cognitive enhancers. Little is known about differences in the acute effects of equally...

Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects

The International Journal of Neuropsychopharmacology May 16, 2017 André Schmidt, Felix Müller, Patrick C. Dolder et al. 41 citations

Background: Psychostimulants such as methylphenidate and modafinil are increasingly used by healthy people for cognitive enhancement purposes, whereas the acute effect of 3,4-methylenedioxymethamphetamine (ecstasy) on cognitive functioning in healthy subjects remains unclear. This study directly compared the acute effects of methylphenidate, modafinil, and 3,4-methylenedioxymethamphetamine on...

DOI: 10.1093/ijnp/pyx037 (opens in new tab) Full text (opens in new tab) MDMA Modafinil Methylphenidate Response inhibition +2

Modern Clinical Research on LSD

Neuropsychopharmacology April 27, 2017 Matthias E. Liechti 230 citations

All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical...

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects

Translational Psychiatry April 4, 2017 Felix Mueller, Claudia Lenz, Patrick C. Dolder et al. 124 citations

Abstract Lysergic acid diethylamide (LSD) induces profound changes in various mental domains, including perception, self-awareness and emotions. We used functional magnetic resonance imaging (fMRI) to investigate the acute effects of LSD on the neural substrate of emotional processing in humans. Using a double-blind, randomised, cross-over study design, placebo or 100 μg LSD were orally...

Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies

Journal of Psychopharmacology April 3, 2017 Kim P. C. Kuypers, Patrick C. Dolder, Johannes G. Ramaekers et al. 88 citations

Previous placebo-controlled experimental studies have shown that a single dose of MDMA can increase emotional empathy in the multifaceted empathy test (MET) without affecting cognitive empathy. Although sufficiently powered to detect main effects of MDMA, these studies were generally underpowered to also validly assess contributions of additional parameters, such as sex, drug use history, trait...

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.

European Neuropsychopharmacology March 2017 Patrick Vizeli, Yasmin Schmid, Katharina Prestin et al.

In vitro studies showed that CYP2C19, CYP2B6, and CYP1A2 contribute to the metabolism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) to 3,4-methylenedioxyamphetamine (MDA). However, the role of genetic polymorphisms in CYP2C19, CYP2B6, and CYP1A2 in the metabolism of MDMA in humans is unknown. The effects of genetic variants in these CYP enzymes on the pharmacokinetics and...

DOI: 10.1016/j.euroneuro.2017.01.008 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxyamphetamine 3,4-methylenedioxymethamphetamine Cyp1a2 Cyp2b6 +2

Safety pharmacology of acute MDMA administration in healthy subjects

Journal of Psychopharmacology February 21, 2017 Patrick Vizeli, Matthias E. Liechti 142 citations

3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is being investigated in MDMA-assisted psychotherapy. The present study characterized the safety pharmacology of single-dose administrations of MDMA (75 or 125 mg) using data from nine double-blind, placebo-controlled, crossover studies performed in the same laboratory in a total of 166 healthy subjects. The duration of the subjective effects...

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects

Clinical Pharmacokinetics February 14, 2017 Patrick C. Dolder, Yasmin Schmid, Andrea E. Steuer et al. 134 citations

BACKGROUND AND OBJECTIVE: Lysergic acid diethylamide (LSD) is used recreationally and in clinical research. The aim of the present study was to characterize the pharmacokinetics and exposure-response relationship of oral LSD. METHODS: We analyzed pharmacokinetic data from two published placebo-controlled, double-blind, cross-over studies using oral administration of LSD 100 and 200 µg in 24 and...

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.

Current Biology February 6, 2017 Katrin H. Preller, Marcus Herdener, Thomas Pokorny et al.

A core aspect of the human self is the attribution of personal relevance to everyday stimuli enabling us to experience our environment as meaningful [1]. However, abnormalities in the attribution of personal relevance to sensory experiences are also critical features of many psychiatric disorders [2, 3]. Despite their clinical relevance, the neurochemical and anatomical substrates enabling...

Mistaking 2C-P for 2C-B: What a Difference a Letter Makes.

Journal of Analytical Toxicology 2017 Adrian Stoller, Patrick C. Dolder, Michael Bodmer et al. 19 citations

2,5-Dimethoxy-4(n)-propylphenethylamine (2C-P) is a synthetic phenethylamine derivative belonging to the large family of the so-called 2C drugs. These compounds can differ significantly in receptor affinity, potency and duration of action, and an important structural difference is the ligand in the 4 position of the phenyl ring, such as propyl in 2C-P or bromine in...

DOI: 10.1093/jat/bkw108 (opens in new tab) Full text (opens in new tab) Chemical structure variation Drug potency Synthetic drugs Adverse drug effects

Interactions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells.

Current Topics in Behavioral Neurosciences 2017 Linda D. Simmler, Matthias E. Liechti

Pharmacological assays carried out in transfected cells have been very useful for describing the mechanism of action of cathinone new psychoactive substances (NPS). These in vitro characterizations provide fast and reliable information on psychoactive substances soon after they emerge for recreational use. Well-investigated comparator compounds, such as methamphetamine,...

DOI: 10.1007/7854_2016_20 (opens in new tab) Full text (opens in new tab) Cathinones Efflux Heterologous expression systems In vitro +4

Alterations of consciousness and mystical-type experiences after acute LSD in humans

Psychopharmacology October 7, 2016 Matthias E. Liechti, Patrick C. Dolder, Yasmin Schmid 203 citations

Mystical-type experiences were infrequent after LSD, possibly because of the set and setting used in the present study. LSD may produce greater or different alterations of consciousness at 200 μg (i.e., a dose that is currently used in psychotherapy in Switzerland) compared with 100 μg (i.e., a dose used in imaging studies). Ego dissolution may reflect plasma levels of LSD, whereas more...

Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.

PLoS One June 15, 2016 Andrea E. Steuer, Corina Schmidhauser, Eva H Tingelhoff et al. 18 citations

3,4-methylenedioxymethamphetamine (MDMA; ecstasy) metabolism is known to be stereoselective, with preference for S-stereoisomers. Its major metabolic step involves CYP2D6-catalyzed demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by methylation and conjugation. Alterations in CYP2D6 genotype and/or phenotype have been associated with higher toxicity. Therefore, the impact of...

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Pharmacogenetics and Genomics June 2, 2016 Yasmin Schmid, Patrick Vizeli, Cédric M. Hysek et al. 52 citations

The role of genetic polymorphisms in cytochrome (CYP) 2D6 involved in the metabolism of 3,4-methylene-dioxymethamphetamine (MDMA, ecstasy) is unclear. Effects of genetic variants in CYP2D6 on the pharmacokinetics and pharmacodynamic effects of MDMA were characterized in 139 healthy individuals (70 men, 69 women) in a pooled analysis of eight double-blind, placebo-controlled crossover studies....

LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality

Neuropsychopharmacology June 1, 2016 Patrick C. Dolder, Yasmin Schmid, Felix Müller et al. 249 citations

Lysergic acid diethylamide (LSD) is used recreationally and has been evaluated as an adjunct to psychotherapy to treat anxiety in patients with life-threatening illness. LSD is well-known to induce perceptual alterations, but unknown is whether LSD alters emotional processing in ways that can support psychotherapy. We investigated the acute effects of LSD on emotional processing using the Face...

Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: a case series.

BMC Pharmacology and Toxicology May 26, 2016 Evangelia Liakoni, Patrick C. Dolder, Katharina Rentsch et al. 24 citations

Although the recreational use of psychoactive substances is common there is only limited systematic collection of data on acute drug toxicity or hospital presentations, in particular regarding novel psychoactive substances (NPS) that have emerged on the illicit market in the last years. We included all cases presenting at the emergency department (ED) of the University Hospital of Basel,...

DOI: 10.1186/s40360-016-0068-7 (opens in new tab) Full text (opens in new tab) Acute toxicity Psychoactive substances Recreational drugs Emergency medicine +1

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

European Neuropsychopharmacology May 20, 2016 Anna Rickli, Olivier D. Moning, Marius C. Hoener et al. 374 citations

The present study investigated interactions between the novel psychoactive tryptamines DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT at monoamine receptors and transporters compared with the classic hallucinogens lysergic acid diethylamide (LSD), psilocin, N,N-dimethyltryptamine (DMT), and mescaline. We investigated binding affinities at human monoamine receptors and determined...

Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects

Journal of Neuroendocrinology February 6, 2016 Petra Strajhar, Yasmin Schmid, Evangelia Liakoni et al. 129 citations

Lysergic acid diethylamide (LSD) is a serotonin 5‐hydroxytryptamine‐2A (5‐HT 2A ) receptor agonist that is used recreationally worldwide. Interest in LSD research in humans waned after the 1970s, although the use of LSD in psychiatric research and practice has recently gained increasing attention. LSD produces pronounced acute psychedelic effects, although its influence on plasma steroid levels...

Neuroimaging in moderate MDMA use: A systematic review

Neuroscience & Biobehavioral Reviews December 30, 2015 Felix Mueller, Claudia Lenz, Markus Steiner et al. 68 citations

MDMA ("ecstasy") is widely used as a recreational drug, although there has been some debate about its neurotoxic effects in humans. However, most studies have investigated subjects with heavy use patterns, and the effects of transient MDMA use are unclear. In this review, we therefore focus on subjects with moderate use patterns, in order to assess the evidence for harmful effects. We searched...

Pharmacokinetics and pharmacodynamics of γ‐hydroxybutyrate in healthy subjects

British Journal of Clinical Pharmacology December 11, 2015 Matthias E. Liechti, Boris B. Quednow, Evangelia Liakoni et al. 57 citations

AIMS: γ-Hydroxybutyrate (GHB) is used as a treatment for narcolepsy and alcohol withdrawal and as a recreational substance. Nevertheless, there are limited data on the pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of GHB in humans. We characterized the pharmacokinetic profile and exposure-psychotropic effect relationship of GHB in humans. METHODS: Two oral doses of GHB (25...

DOI: 10.1111/bcp.12863 (opens in new tab) Pharmacokinetics Sedation Pharmacodynamics Stimulant +7

Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).

Neuropharmacology December 1, 2015 Anna Rickli, Dino Luethi, Julian Reinisch et al. 216 citations

N-2-methoxybenzyl-phenethylamines (NBOMe drugs) are newly used psychoactive substances with poorly defined pharmacological properties. The aim of the present study was to characterize the receptor binding profiles of a series of NBOMe drugs compared with their 2,5-dimethoxy-phenethylamine analogs (2C drugs) and lysergic acid diethylamide (LSD) in vitro. We investigated the binding affinities of...

DOI: 10.1016/j.neuropharm.2015.08.034 (opens in new tab) Full text (opens in new tab) Affinity Hallucinogens Novel psychoactive substances Phenethylamines +1

Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans.

Drug metabolism and disposition: the biological fate of chemicals December 2015 Andrea E. Steuer, Corina Schmidhauser, Yasmin Schmid et al.

Generally, pharmacokinetic studies on 3,4-methylenedioxymethamphetamine (MDMA) in blood have been performed after conjugate cleavage, without taking into account that phase II metabolites represent distinct chemical entities with their own effects and stereoselective pharmacokinetics. The aim of the present study was to stereoselectively investigate the pharmacokinetics of intact glucuronide...